BeyondSpring, a global biopharmaceutical company focusing on immune-oncology therapy treatments for cancer patients, received today (9/8) breakthrough therapy designations (BTD) from the U.S. Food and Drug Administration (FDA) as well as the China National Medical Products Administration (NMPA) for their chemotherapy-induced neutropenia indication Plinabulin. The BTD is meant to streamline the drug development process so patients can have access to treatment quicker and lives can be saved. “[The BTD] should expedite Plinabulin’s move into the clinic, which is beneficial for patients explains Plinabulin’s CIN studies global Principal Investigator Douglas Blayney, M.D. “over 80 percent of cancer patients undergoing chemotherapy may still experience Grade 4 neutropenia, which could lead to severe infection, hospitalization and even death. Thus, CIN still represents an unmet medical need.”

Read more here.

More on: